Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1

Blood

Volumn 96, Issue 6, 2000, Pages 2093-2099

  Wang, Qin ^a   Miyakawa, Yoshitaka ^a   Fox, Norma ^a   Kaushansky, Kenneth ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE RECEPTOR; HORMONE RECEPTOR; JANUS KINASE; REGULATOR PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSORS OF CYTOKINE SIGNALING PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; LYMPHOPROLIFERATIVE DISEASE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TOXICOKINETICS; VIRUS HEPATITIS;

EID: 0034665904     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.6.2093.h8002093_2093_2099     Document Type: Article

References (68)

1. Interferons in the management of viral hepatitis
2. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference
3. Hepatitis G virus and human immunodeficiency virus coinfection: Response to interferon-alpha therapy
4. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
5. New drugs in essential thrombocythemia and polycythemia vera
6. Maintenance therapy with interferon alfa 2b in Hodgkin's disease
7. Recombinant interferon-alpha therapy in patients with follicular lymphoma
8. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
9. Side effects of alpha interferon in chronic hepatitis C
10. Interferon-induced thrombocytopenia: Is it time for thrombopoietin?
11. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment
12. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C
13. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C
14. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection
15. Alpha-interferon: Differential suppression of colony growth from human erythroid, myeloid, and megakaryocytic hematopoietic progenitor cells
16. Effects of recombinant human interferon alpha on human megakaryocyte and fibroblast colony formation
17. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells
18. In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia
19. Recombinant alpha-interferon inhibits colony formation of bone marrow fibroblast progenitor cells (CFU-F)
20. The effect of interferon alpha on beta 1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia
21. Inhibition of human erythroid colony-forming units by interferons α and β: Differing mechanisms despite shared receptors
22. Thrombopoietin: The primary regulator of platelet production
23. Negative regulators of cytokine signal transduction
24. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
25. Dissecting the thrombopoietin receptor: Functional elements of the mpl cytoplasmic domain
26. Stromal cell derived factor 1 acts synergistically with thrombopoietin to enhance the development of megakaryocytic progenitor cells
27. Thrombopoietin signal transduction in purified murine megakaryocytes
28. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin
29. Thrombopoietin-induced activation of the mitogen activated protein kinase pathway in normal megakaryocytes: Role in endomitosis
30. Stimulation of tyrosine kinase activity by MPL-ligand (thrombopoietin)
31. Thrombopoietin activates a STAT5-like factor in hematopoietic cells
32. The thrombopoietin receptor c-Mpl activates JAK2 and TYK2 tyrosine kinases
33. Megakaryocyte growth and development factor and interleukin-3 induce patterns of protein-tyrosine phosphorylation that correlate with dominant differentiation over proliferation of mpl-transfected 32D cells
34. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets
35. SHP-1 phosphatase C-terminus interacts with novel substrates p32/p30 during erythropoietin and interleukin-3 mitogenic responses
36. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1
37. A family of cytokine-inducible inhibitors of signalling
38. Interferon-alpha inhibits proliferation of Ba/F3 cells by interfering with interleukin-3 action
39. Growth inhibitory effect of interferon-β is associated with the induction of cyclin-dependent kinase inhibitor p27(Kip1) in a human gastric carcinoma cell line
40. A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation
41. Inhibitory effect of interferon on mouse megakaryocytic progenitor cells in culture
42. Interferon gamma inhibits proliferation, but not commitment, of murine granulocyte macrophage progenitors
43. Interferon-γ and human megakaryopoiesis
44. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon γ to produce erythroid cell apoptosis
45. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors
46. The hematopoietin receptor super-family
47. Cytokine receptor signaling
48. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
49. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins
50. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase
51. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling
52. Proteins of transcription factor ISGF-3: One gene encodes the 91 and 84-kDa ISGF-3 proteins that are activated by interferon α
53. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: Identification of potential binding sites
54. Regulation of the erythropoietin receptor and involvement of JAK2 in differentiation of J2E erythroid cells
55. Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev)
56. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors
57. Structure and function of a new STAT-induced STAT inhibitor
58. Interferon-β interrupts interleukin-6-dependent signaling events in myeloma cells
59. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells
60. A Janus kinase inhibitor, JAB, is an interferon-γ-inducible gene and confers resistance to interferons
61. CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells
62. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor
63. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality
64. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1
65. Recombinant human interferon gamma therapy for osteopetrosis
66. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer
67. SOCS3 is essential in the regulation of fetal liver erythropoiesis
68. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1